Telormedix elected member of multi-million collaborative research programme

The research programme “TIMER” was launched on January 1 2012 to accelerate the development of novel and powerful strategies to fight inflammation. Scientists from nine research partners in four European countries and three research partners in Brazil will collaborate in this new programme.

Telormedix’s contribution to the project, coordinated by Alcide Barberis, Head of Research and Collaborations, will primarily draw on its expertise in the field of modulators of Toll-like Receptors (TLRs), which play a key role in inflammatory diseases, as well as on the recent advances in the characterization of its TLR modulators as first-in-class and efficacious anti-inflammatory compounds.

Alcide Barberis commented: “We are privileged to be playing such a strong part in this important international collaboration. We have great hopes that this collaboration will deliver new approaches to the treatment of diseases of unmet need.”

Telormedix, founded in October 2007, is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and autoimmune diseases. Located in Ticino, Telormedix is led by a highly experienced management team and backed by an international consortium of venture capitalists Aravis Venture (Basel, Switzerland) and Proquest Investments (Princeton-San Diego, USA)